Roth Mkm Upgrades Tilray Brands (NASDAQ:TLRY) to Buy

Tilray Brands (NASDAQ:TLRY) was upgraded by equities research analysts at Roth Mkm from a “neutral” rating to a “buy” rating in a report released on Thursday, MarketBeat Ratings reports. The brokerage presently has a $10.00 target price on the stock. Roth Mkm’s price target suggests a potential upside of 52.67% from the company’s previous close.

Several other equities analysts have also issued reports on the company. Wall Street Zen upgraded Tilray Brands from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tilray Brands in a research note on Wednesday, January 21st. Canaccord Genuity Group started coverage on Tilray Brands in a research report on Tuesday, January 27th. They issued a “hold” rating on the stock. ATB Cormark Capital Markets raised Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 10th. Finally, Zacks Research raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. Three investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $11.20.

Tilray Brands Stock Performance

NASDAQ TLRY opened at $6.55 on Thursday. The company has a current ratio of 2.79, a quick ratio of 1.72 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $763.14 million, a price-to-earnings ratio of -0.48 and a beta of 2.00. The firm’s 50 day simple moving average is $7.27 and its 200 day simple moving average is $10.19. Tilray Brands has a 1 year low of $3.51 and a 1 year high of $23.20.

Tilray Brands (NASDAQ:TLRY) last announced its quarterly earnings data on Wednesday, April 1st. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.10). Tilray Brands had a negative net margin of 156.51% and a negative return on equity of 3.31%. The firm had revenue of $206.73 million for the quarter, compared to analyst estimates of $201.35 million. During the same quarter in the prior year, the firm earned ($0.87) earnings per share. As a group, research analysts expect that Tilray Brands will post -0.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tilray Brands

Several hedge funds have recently modified their holdings of the company. AQR Capital Management LLC increased its holdings in Tilray Brands by 1,839.7% in the 1st quarter. AQR Capital Management LLC now owns 607,054 shares of the company’s stock worth $399,000 after purchasing an additional 575,757 shares in the last quarter. Swiss National Bank grew its holdings in shares of Tilray Brands by 6.1% during the second quarter. Swiss National Bank now owns 1,928,138 shares of the company’s stock worth $799,000 after purchasing an additional 111,500 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Tilray Brands in the second quarter valued at approximately $112,000. J.W. Cole Advisors Inc. increased its stake in shares of Tilray Brands by 203.2% in the second quarter. J.W. Cole Advisors Inc. now owns 71,890 shares of the company’s stock valued at $30,000 after buying an additional 48,177 shares during the period. Finally, Cerity Partners LLC raised its holdings in Tilray Brands by 98.5% in the 2nd quarter. Cerity Partners LLC now owns 92,560 shares of the company’s stock valued at $38,000 after buying an additional 45,929 shares during the last quarter. Institutional investors and hedge funds own 9.35% of the company’s stock.

Key Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Roth/MKM upgraded TLRY to Buy (new $10 price target), citing the Q3 results as a catalyst for improved sentiment—this upgrade supports near-term buying interest. Roth upgrade coverage
• Positive Sentiment: Jefferies reiterated a Buy and kept a $24 price target, pointing to strong cannabis sales and better medium‑term visibility; a high PT from a major shop increases upside narratives for investors. Jefferies note
• Positive Sentiment: Regulatory tailwind: reports that the FDA won’t enforce some CBD regulations spurred sector buying, lifting Tilray alongside peers and improving the outlook for CBD revenue. FDA/CBD coverage
• Positive Sentiment: Product/brand news — Tilray Beverages’ Shock Top launched a high‑ABV beer (High Voltage), a growth/innovation signal for the beverages segment that can help top-line recovery over time. Shock Top launch
• Neutral Sentiment: Analyst/deep-dive pieces see TLRY as improving but still mixed: commentary highlights revenue growth, international cannabis up ~73% in Q3, and narrowing losses but cautions on margins, cash flow and M&A execution. This frames TLRY as a recovery story with execution risk. Seeking Alpha analysis
• Neutral Sentiment: Zacks and other commentary call Q3 mixed—revs beat slightly and losses narrowed, but beverage weakness and margin pressure temper bullish cases. Zacks piece
• Negative Sentiment: Earnings miss: TLRY reported Q3 EPS of -$0.24 vs. consensus -$0.14 (revenue ~$206.7M vs. est. ~$201.4M). The EPS shortfall on the call raised concerns about margins and profitability despite top-line improvements. MSN earnings transcript InsiderMonkey transcript
• Negative Sentiment: ATB Cormark trimmed its price target to $9.00 and moved to sector perform, signaling more conservative near‑term expectations and adding selling pressure from cautious analysts. ATB Cormark note

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.